Journal article
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
Abstract
PURPOSE: Gastrointestinal microbleeding, as assessed by the measurement of (51)chromium-labeled red blood cells, is a marker of the mucosal injury associated with the use of nonsteroidal anti-inflammatory drugs. This study tested the hypotheses that cyclooxygenase-2 specific inhibition with rofecoxib would cause less fecal blood loss than a therapeutic dose of ibuprofen and would be equivalent to placebo.
SUBJECTS AND METHODS: In this …
Authors
Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
Journal
The American Journal of Medicine, Vol. 109, No. 3, pp. 201–206
Publisher
Elsevier
Publication Date
8 2000
DOI
10.1016/s0002-9343(00)00470-8
ISSN
0002-9343
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAnti-Inflammatory Agents, Non-SteroidalChromium RadioisotopesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDrug Administration ScheduleErythrocytesGastrointestinal HemorrhageHumansIbuprofenIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOccult BloodOsteoarthritisProstaglandin-Endoperoxide SynthasesRadionuclide ImagingRadiopharmaceuticalsReference ValuesSulfonesTreatment Outcome